BioLineRx annual gross margin
2023
2024
2025
BioLineRx Gross Margin Growth & History (BLRX)
BioLineRx's gross margin was 80.51% for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 80.51% | +12.52 pp |
| 2024 | 2024-12-31 | 67.99% | +44.91 pp |
| 2023 | 2023-12-31 | 23.08% | — |
BioLineRx quarterly gross margin
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 79.93% | +3.62 pp |
| Q1 2026 | 2026-03-31 | 80.08% | −6.58 pp |
| Q4 2025 | 2025-12-31 | 79.38% | — |
| Q3 2025 | 2025-09-30 | 80.33% | — |
| Q2 2025 | 2025-06-30 | 76.32% | −7.05 pp |
| Q1 2025 | 2025-03-31 | 86.67% | — |
| Q2 2024 | 2024-06-30 | 83.37% | — |
BioLineRx gross margin trends
Between the periods ended 2023-12-31 and 2025-12-31, BioLineRx's gross margin increased from 23.08% to 80.51%, a change of +57.43 percentage points. The latest reported quarter, Q2 2026, shows 79.93%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗